Abeona Therapeutics to Present at Multiple Upcoming Conferences
May 19 2017 - 8:05AM
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage
biopharmaceutical company focused on developing novel gene
therapies for life-threatening rare diseases, announced that
members of the management team will present at the following
upcoming conferences:
Event: Cell & Gene ExchangePanelist:
President and CEO, Timothy J. Miller, Ph.D.Panel: “Best Practices
for Partnering with Disease Foundations and Patient Groups”Date:
Monday, May 22nd Time: 3:15 PM ET
Presenter: President and CEO, Timothy J. Miller, Ph.D.Abeona
Company Presentation Date: Tuesday, May 23rdTime: 2:30 pm ETRoom:
Atrium BallroomLocation: Ronald Reagan Building, Washington,
D.C.Website: https://ebdgroup.knect365.com/cellgene-exchange/
Event: UBS Global Healthcare
ConferencePresenter: Chief Operating Officer, Jeffrey B.
Davis Date: Tuesday, May 23rdTime: 2:30 PM ETRoom: Ballroom
VLocation: Grand Hyatt, New York, NYWebcast:
www.ibb.ubs.com/Conferences
Event: Neurotech Investing and Partnering
ConferencePanelist: President and CEO, Timothy J. Miller,
Ph.D.Panel: “Targeting Orphan Diseases”Date: Thursday, June 1st
Time: 3:45 PM PT Location: Park Central Hotel, San Francisco,
CAWebsite: http://www.neurotechpartnering.com/
Abeona Recent Highlights
ABO-102 gene therapy program for
Sanfilippo syndrome Type A: Abeona announced top-line data
for Phase 1/2 MPS IIIA gene therapy trial at ASGCT --Positive
dose response in central nervous system with 60.7% +/- 8.8%
reduction of disease-causing heparan sulfate GAG observed in Cohort
2 --Reduction of disease manifestation observed in decreased
liver volume of 14.81% (+/- 1.2%) --ABO-102
well-tolerated in six subjects through more than 1,100 days
cumulative follow-up with no Serious Adverse Events--Cohort 1
demonstrated stabilized or improved Leiter Nonverbal IQ scores at
six months Abeona received regulatory approval to initiate
ABO-102 gene therapy clinical trial in Australia for patients with
MPS IIIA
EB-101 gene therapy program for severe
form of Epidermolysis Bullosa: Abeona provided an update
for Phase 1/2a gene therapy to the Society for Investigative
Dermatology Conference--EB-101 demonstrated significant wound
healing (defined as greater than 50% healed) in 100% of treated
wounds (36/36) at 3 months; 89% (32/36) at 6 months, 83% (20/24) at
12 months, 88% (21/24) at 24 months and 100% (6/6) at 36 months
post-administration--Clinical endpoints supported by data from
Natural History Study observations from 1,436 wounds in 128
patients with Recessive Dystrophic Epidermolysis Bullosa
(RDEB)Abeona was granted Orphan Drug Designation for EB-101 in
Epidermolysis Bullosa by the European Medicines Agency (EMA)
Committee for Orphan Medicinal Products
About Abeona: Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company
developing gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an
adeno-associated virus (AAV) based gene therapy for Sanfilippo
syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts)
for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is
also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B
(MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten
disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile
Batten disease (INCL), EB-201 for epidermolysis bullosa (EB),
ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302
using a novel CRISPR/Cas9-based gene editing approach to gene
therapy for rare blood diseases. In addition, Abeona has a
plasma-based protein therapy pipeline, including SDF Alpha™
(alpha-1 protease inhibitor) for inherited COPD, using its
proprietary SDF™ (Salt Diafiltration) ethanol-free process. For
more information, visit www.abeonatherapeutics.com.
Investor Contact:Christine Silverstein Vice
President, Investor Relations Abeona Therapeutics Inc. +1
(212)-786-6212 csilverstein@abeonatherapeutics.com
Media Contact:Andre’a Lucca Vice President,
Communications & Operations Abeona Therapeutics Inc. +1
(212)-786-6208alucca@abeonatherapeutics.com
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements include without limitation the
statement that the ability to develop our products and
technologies; treated and monitored in the EB-101 clinical trial,
and that studies will continue to indicate that EB-101 is
well-tolerated and may offer significant improvements in wound
healing; the addition of two additional global clinical sites will
accelerate our ability to enroll and evaluate ABO-102 as a
potential treatment for patients with Sanfilippo syndrome type A,
or MPS IIIA. Such statements are subject to numerous risks and
uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition; the ability to secure
licenses for any technology that may be necessary to commercialize
our products; the ability to achieve or obtain necessary regulatory
approvals; the impact of changes in the financial markets and
global economic conditions; our belief that initial signals of
biopotency and clinical activity, which suggest that ABO-102
successfully reached target tissues throughout the body, including
the central nervous system and the increased reductions in CNS GAG
support our approach for intravenous delivery for subjects with
Sanfilippo syndromes, and other risks as may be detailed from time
to time in the Company's Annual Reports on Form 10-K and quarterly
reports on Form 10-Q and other reports filed by the Company with
the Securities and Exchange Commission. The Company undertakes no
obligations to make any revisions to the forward-looking statements
contained in this release or to update them to reflect events or
circumstances occurring after the date of this release, whether as
a result of new information, future developments or otherwise.
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Sep 2023 to Sep 2024